This company listing is no longer active
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥0.72 |
| 52 Week High | CN¥1.04 |
| 52 Week Low | CN¥0.72 |
| Beta | 0.21 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| SHEZ.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.02% | -0.6% |
| 1Y | n/a | 15.8% | 22.2% |
Return vs Industry: Insufficient data to determine how SHEZ.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SHEZ.F performed against the US Market.
Price Volatility
| SHEZ.F volatility | |
|---|---|
| SHEZ.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SHEZ.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SHEZ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,046 | Yu Shan | www.hepalink.com |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamentals Summary
| SHEZ.F fundamental statistics | |
|---|---|
| Market cap | US$2.42b |
| Earnings (TTM) | US$61.75m |
| Revenue (TTM) | US$1.02b |
43.3x
P/E Ratio2.6x
P/S RatioIs SHEZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHEZ.F income statement (TTM) | |
|---|---|
| Revenue | CN¥7.13b |
| Cost of Revenue | CN¥4.85b |
| Gross Profit | CN¥2.28b |
| Other Expenses | CN¥1.85b |
| Earnings | CN¥431.54m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.29 |
| Gross Margin | 32.01% |
| Net Profit Margin | 6.05% |
| Debt/Equity Ratio | 55.2% |
How did SHEZ.F perform over the long term?
See historical performance and comparison